Literature DB >> 9565682

Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells.

G Michel1, M Mercken, M Murayama, K Noguchi, K Ishiguro, K Imahori, A Takashima.   

Abstract

One of the histopathological markers in Alzheimer's disease is the accumulation of hyperphosphorylated tau in neurons called neurofibrillary tangles (NFT) composing paired helical filaments (PHF). Combined tau protein kinase II (TPK II), which consists of CDK5 and its activator (p23), and glycogen synthase kinase-3beta (GSK-3beta) phosphorylate tau to the PHF-form in vitro. To investigate tau phosphorylation by these kinases in intact cells, the phosphorylation sites were examined in detail using well-characterized phosphorylation-dependent anti-tau antibodies after overexpressing the kinases in COS-7 cells with a human tau isoform. The overexpression of tau in COS-7 cells showed extensive phosphorylation at Ser-202 and Ser-404. The p23 overexpression induced a mobility shift of tau, but most of the phosphorylation sites overlapped the endogenous phosphorylation sites. GSK-3beta transfection showed the phosphorylation at Ser-199, Thr-231, Ser-396, and Ser-413. Triplicated transfection resulted in phosphorylation of tau at 8 observed sites (Ser-199, Ser-202, Thr-205, Thr-231, Ser-235, Ser-396, Ser-404, and Ser-413). Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9565682     DOI: 10.1016/s0304-4165(97)00139-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  22 in total

1.  Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy.

Authors:  Nimrod Miller; Zhihua Feng; Brittany M Edens; Ben Yang; Han Shi; Christie C Sze; Benjamin Taige Hong; Susan C Su; Jorge A Cantu; Jacek Topczewski; Thomas O Crawford; Chien-Ping Ko; Charlotte J Sumner; Long Ma; Yong-Chao Ma
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

2.  Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.

Authors:  M K Ahlijanian; N X Barrezueta; R D Williams; A Jakowski; K P Kowsz; S McCarthy; T Coskran; A Carlo; P A Seymour; J E Burkhardt; R B Nelson; J D McNeish
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

3.  Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau.

Authors:  Kentaro Tanemura; Miyuki Murayama; Takumi Akagi; Tsutomu Hashikawa; Takashi Tominaga; Michinori Ichikawa; Haruyasu Yamaguchi; Akihiko Takashima
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

4.  Loss of Hsp110 leads to age-dependent tau hyperphosphorylation and early accumulation of insoluble amyloid beta.

Authors:  Binnur Eroglu; Demetrius Moskophidis; Nahid F Mivechi
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

5.  The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.

Authors:  Xiaochuan Wang; Julie Blanchard; Erik Kohlbrenner; Nathalie Clement; R Michael Linden; Aurelian Radu; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  FASEB J       Date:  2010-07-22       Impact factor: 5.191

Review 6.  Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.

Authors:  Dick Terwel; Ilse Dewachter; Fred Van Leuven
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 7.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22

8.  Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau.

Authors:  A Takashima; M Murayama; O Murayama; T Kohno; T Honda; K Yasutake; N Nihonmatsu; M Mercken; H Yamaguchi; S Sugihara; B Wolozin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 9.  Discovery of compounds that will prevent tau pathology.

Authors:  Kenneth S Kosik; Jae Ahn; Ross Stein; Li-An Yeh
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

10.  Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies.

Authors:  Wenjie Luo; Fei Dou; Anna Rodina; Sophorn Chip; Joungnam Kim; Qi Zhao; Kamalika Moulick; Julia Aguirre; Nian Wu; Paul Greengard; Gabriela Chiosis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.